Olanzapine and Fluoxetine
Brand Names: Olanzapine and Fluoxetine Generic
Methodology & AI Transparency ⓘ
Olanzapine and Fluoxetine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder .
- 2 Real-world patient consensus: Real-world cohort score of 90% across 17 de-identified Olanzapine and Fluoxetine entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $171.64 mail/discount cash up to $420.52 uninsured retail (federal NADAC $4.0280).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Olanzapine and Fluoxetine: cutaneous rash (5.2%), orthostatic hypotension (1.8%), application-site erythema (7.8%).
Ask our AI Specialists anything about Olanzapine and Fluoxetine
Olanzapine and Fluoxetine Mechanism, CYP450 Pathways & DailyMed Monograph
Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder . Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) . Olanzapine and fluoxetine capsules combine olanzapine, an atypical antipsychotic and fluoxetine, a selective serotonin reuptake inhibitor, indicated for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder (1) Treatment Resistant Depression (1)
12.1 Mechanism of Action Although the exact mechanism of olanzapine and fluoxetine capsules is unknown, it has been proposed that the activation of 3 monoaminergic neural systems (serotonin, norepinephrine, and dopamine) is responsible for its enhanced antidepressant effect. In animal studies, olanzapine and fluoxetine in combination has been shown to produce synergistic increases in norepinephrine and dopamine release in the prefrontal cortex compared with either component alone, as well as increases in serotonin.
Following administration (6 mg/1 / 25 mg/1 Capsule), Olanzapine and Fluoxetine achieves < 5% transdermal or mucosal systemic uptake from Olanzapine and Fluoxetine bioavailability and initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (olanzapine and fluoxetine) onset, governed by a Negligible circulating terminal half-life following local Olanzapine and Fluoxetine application terminal half-life through local esterase/enzymatic cleavage of olanzapine and fluoxetine with minimal hepatic cytochrome burden.
Before initiating Olanzapine and Fluoxetine at 6 mg/1 / 25 mg/1 Capsule, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to olanzapine and fluoxetine; clinical scenarios where atypical antipsychotic exposure from olanzapine and fluoxetine poses unacceptable risk. Logged tolerability patterns center on application-site erythema (7.8% of reports), mild local dryness (6.4% of reports), transient stinging (5.4% of reports).
Verify medication reconciliation lists so Olanzapine and Fluoxetine is not inadvertently duplicated with another atypical antipsychotic.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Olanzapine and Fluoxetine dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Olanzapine and Fluoxetine
- Clinical scenarios where atypical antipsychotic exposure from Olanzapine and Fluoxetine poses unacceptable risk
Logged Side-Effect Incidence (17 Reports)
Olanzapine and Fluoxetine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Olanzapine and Fluoxetine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of: What a 281-Participant Study Found Conclusion: In this 56-week post hoc analysis of patients initially experiencing an acute exacerbation of schizophrenia, OLZ/SAM was associated with significant and durable improvement in negative symptoms of schizophrenia,... The Journal of clinical psychiatry • 2026-03-09 • Phase III Randomized Trial | N = 281 | 93/100 | PMID 41944743 ↗ |
| New Insights on Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced: What a 690-Participant Study Found This trial did not provide sufficient evidence to support that deletion of the NK-1 receptor antagonist was as good as keeping it, as a part of a 4-drug antiemetic regimen for highly emetogenic chemotherapy. The oncologist • 2023-08-03 • Phase III Randomized Trial | N = 690 | 93/100 | PMID 37284847 ↗ |
| Can This Approach Help? Inside the Latest Research on Central nervous system symptom burden and clinical implications for antiemetic CNS symptom burden was associated with suboptimal CINV control, while 5 mg of olanzapine maintained superior antiemetic efficacy across CNS symptom strata. The oncologist • 2026-09-09 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42714265 ↗ |
| Can This Approach Help? Inside the Latest Research on Olanzapine combined with standard antiemetics for the prevention of nausea and Conclusion This trial provides the first high-level evidence supporting the olanzapine-based four-drug combination to prevent CINV in GCT patients undergoing 5-day cisplatin-based chemotherapy. European journal of cancer (Oxford, England : 1990) • 2025-06-03 • Phase III Randomized Trial | N = 77 | 88/100 | PMID 40311506 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of olanzapine exposure on relapse and brain structure in patients with Our findings suggest that, within its therapeutic range, the effect of olanzapine on relapse or cortical thickness does not depend on its dosage or SSC. Molecular psychiatry • 2024-08-15 • Randomized Controlled Trial | N = 118 | 88/100 | PMID 38503927 ↗ |
Olanzapine and Fluoxetine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $4.0280/unit (~$120.84/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $420.52 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $171.64 / mo | View logs ↓ |
| Hims & Hers Direct Cash Pharmacy (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $49.00/mo program | Program details |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Olanzapine and Fluoxetine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Olanzapine and Fluoxetine RxNorm Concept ID | 403969 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $4.0280 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $420.52 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $171.64 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Olanzapine and Fluoxetine Patient Community, Cohort Filters & Dosage Logs
Cross-verified Olanzapine and Fluoxetine (atypical antipsychotic) monograph synthesizing RxNorm 403969, openFDA FAERS signals, and $171.64–$420.52 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Olanzapine and Fluoxetine community threads and patient logs by age, biological sex, dosage, and treatment duration.